We evaluated the immunogenicity and reactogenicity of diphtheria, tetanus, whole-cell pertussis and hepatitis B (DTPw-HB) combination vaccine manufactured by Shantha Biotechnics Pvt Ltd, Hyderabad, India in healthy infants between 6 and 8 weeks of age. Overall 123 infants (male:female ratio, 1:1.3) were recruited, of which 112 received all three doses of the vaccine at 6, 10 and 14 weeks of age...

objective: to compare immunogenicity of a recombinant hepatitis b (hb) vaccine in two groups of neonates born in two cities of iran with different geographic and ethnic backgrounds.   materials and methods: ten micrograms of a recombinant hb vaccine was administered under field condition to iranian healthy neonates at 0, 1.5 and 9 months intervals. the subjects consisted of two groups of 290 an...

Objective: To compare immunogenicity of a recombinant hepatitis B (HB) vaccine in two groups of neonates born in two cities of Iran with different geographic and ethnic backgrounds.   Materials and Methods: Ten micrograms of a recombinant HB vaccine was administered under field condition to Iranian healthy neonates at 0, 1.5 and 9 months intervals. The subjects consisted of two groups of 290 an...

Studies on gene therapy for hemophilia B (HB) using adeno-associated viral (AAV) vectors showed that the safety of a given strategy is directly related to the vector dose. To overcome this limitation, we sought to test the efficacy and the risk of immunogenicity of a novel factor IX (FIX) R338L associated with ∼ 8-fold increased specific activity. Muscle-directed expression of canine FIX-R338L ...

OBJECTIVE The DTPw-HB/Hib pentavalent combination vaccine has been developed following recommendations of the World Health Organization for the introduction of hepatitis B (HB) and Haemophilus influenzae type b (Hib) vaccines into routine childhood vaccination programs. The objectives of this study were to: 1) analyze the immunogenicity and the reactogenicity of the DTPw-HB/Hib pentavalent comb...

OBJECTIVE To evaluate the safety and immunogenicity of an indigenous hepatitis B, diphtheria, tetanus and B. pertussis tetravalent vaccine (Shantetra) in comparison with Tritanrix HBTM in healthy Indian infants. DESIGN Multicentric, randomized, single blind intention-to-treat study with 12-18 weeks of follow up period. SETTING 5 out patient departments at tertiary care referral centers acro...

Diisocyanates (dNCOs) are low molecular weight chemical sensitizers that react with autologous proteins to produce neoantigens. dNCO-haptenated proteins have been used as immunogens for generation of dNCO-specific antibodies and as antigens to screen for dNCO-specific antibodies in exposed individuals. Detection of dNCO-specific antibodies in exposed individuals for diagnosis of dNCO asthma has...

Emerging successful clinical data on gene therapy using adeno-associated viral (AAV) vector for hemophilia B (HB) showed that the risk of cellular immune response to vector capsid is clearly dose dependent. To decrease the vector dose, we explored AAV-8 (1-3 × 10(12) vg/kg) encoding a hyperfunctional factor IX (FIX-Padua, arginine 338 to leucine) in FIX inhibitor-prone HB dogs. Two naïve HB dog...

BACKGROUND Neonatal immunization with hepatitis B (HB) vaccine induces protective levels of antibody (anti-HBs > or =10 IU/L) in a majority of vaccines. However, the duration of protection after HB vaccination in infants is unknown. A smaller proportion of children vaccinated beginning at birth with three doses of HB vaccine were found to have protective titers 5-10 years after initial vaccinat...